The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

[1]  T. Olencki,et al.  Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibitors. , 2018 .

[2]  W. Rathmell,et al.  Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[4]  T. Choueiri,et al.  Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update , 2018, European journal of cancer.

[5]  T. Choueiri,et al.  Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. , 2018, The Lancet. Oncology.

[6]  R. Motzer,et al.  Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma , 2018, Clinical Cancer Research.

[7]  C. Porta,et al.  Sorafenib dose escalation in treatment‐naïve patients with metastatic renal cell carcinoma: a non‐randomised, open‐label, Phase 2b study , 2017, BJU international.

[8]  P. Nathan,et al.  Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ. , 2017 .

[9]  B. Rini,et al.  Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma , 2017, Clinical genitourinary cancer.

[10]  B. Rini,et al.  A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Porta,et al.  How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma , 2017, Expert review of anticancer therapy.

[12]  S. Swann,et al.  Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma , 2014, British Journal of Cancer.

[13]  C. Porta,et al.  Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries , 2014, Cancer medicine.

[14]  A. Kiss,et al.  Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.

[15]  T. Bathala,et al.  Adult UrologyOncology: Adrenal/Renal/Upper Tract/BladderClinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules , 2014 .

[16]  T. Choueiri,et al.  Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients , 2014, British Journal of Cancer.

[17]  N. Vogelzang,et al.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.

[18]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[19]  R. Motzer,et al.  Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis , 2013, Journal of clinical pharmacology.

[20]  E. Jonasch,et al.  Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients , 2012, Clinical Cancer Research.

[21]  J. Burke,et al.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Motzer,et al.  A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[24]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Rini.  Sunitinib , 2007, Reactions Weekly.

[26]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[27]  W. Bro,et al.  Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). , 2006, The journal of supportive oncology.

[28]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Bjarnason,et al.  Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma. , 2018, Urologic oncology.

[30]  A. Kiss,et al.  Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.

[31]  R. Motzer,et al.  A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.